

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 5 (Canceled)

6. (Currently Amended) A method of reducing overnight insulin requirement of a patient suffering from Type 1 diabetes mellitus comprising administering insulin and [a] the growth hormone (GH) antagonist pegvisomant to a patient suffering therefrom during the evening.

7. (Currently Amended) A method according to claim 6 comprising administering to the patient a daily dose of the GH antagonist pegvisomant and less frequent overnight infusions of insulin together with a hyperinsulinaemic euglycaemic clamp.

8. (Original) A method according to claim 7 wherein said overnight insulin infusions are administered at approximately three-weekly intervals.

9. (Cancelled)

10. (Currently Amended) A method according to claim ~~9~~ 6 wherein each daily dose of pegvisomant (~~SOMAVERT®~~) is from 1 mg to 20 mg.

11. (Currently Amended) A method according to ~~claim 11~~ claim 10 wherein each daily dose of pegvisomant is from 5 mg to 10 mg.

12. (Canceled)

13. (Currently Amended) A method of treating a patient suffering from both Type 1 diabetes mellitus and from dawn phenomenon comprising administering insulin and [a] the growth hormone (GH) antagonist pegvisomant to a patient.